Business Context and Reporting Period
Company: Pacific Biosciences of California, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2015
Event: Entry into a material definitive agreement to amend an existing equity offering sales agreement.
Key Financial Metrics and Capital Structure
This filing does not contain specific revenue, profit, or cash flow figures. However, it references unaudited financial statements (Exhibit 99.1) and updated Management's Discussion and Analysis (Exhibit 99.2) incorporated by reference.
- Equity Offering Capacity: The Company may offer and sell up to an aggregate offering price of $30.0 million of common stock.
- Commission: The sales agent, Cantor Fitzgerald & Co., will receive a commission of 3.0% of the gross sales price per share sold.
- Use of Proceeds: Proceeds are intended for general corporate purposes, including capital expenditures and working capital.
Material Changes and Agreements
On February 3, 2015, the Company entered into Amendment No. 2 to its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. (originally dated October 5, 2012, and amended November 8, 2013).
- Amendment Details: The amendment increases the "Maximum Amount" of shares that can be sold under the agreement to $30.0 million. This amount is in addition to shares previously sold under the original agreement and Amendment No. 1.
- Sale Method: Shares may be sold via "at-the-market" offerings on The NASDAQ Global Select Market or through other permitted methods, including privately negotiated transactions.
- Termination: The offering terminates upon the sale of all shares subject to the agreement or earlier termination by either party.
Outlook, Risks, and Unusual Items
The Company has updated its disclosure regarding Management's Discussion and Analysis, Business, and Risk Factors (Exhibit 99.2). The filing notes that the Company is not obligated to make any sales of shares under the agreement. The offering is subject to the limitations of the effective Registration Statement on Form S-3 and the number of authorized but unissued shares.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited Consolidated Balance Sheets, Statements of Operations, and Cash Flows referenced in the filing.
- Examine Exhibit 99.2 for the updated Management's Discussion and Analysis and Risk Factors.
- Verify the current number of authorized but unissued shares to confirm the $30.0 million cap is not exceeded by the total authorized share count.
- Monitor future filings for actual sales volumes and proceeds generated under this "at-the-market" agreement.